Aulos BioscienceAulos Bioscience
  • Our Approach
    • Overview
    • Platform
    • Abstracts and Publications
  • Our Pipeline
    • Overview
  • About Us
    • Overview
    • Leadership
    • Board of Directors
    • Investors
    • Corporate Presentation
    • Mission and Values
  • Newsroom
    • Latest News
    • Media Inquiries
  • Careers
    • Join the team
  • Contact
    • General Inquiries
Search
  • Our Approach
    • Overview
    • Platform
    • Abstracts and Publications
  • Our Pipeline
    • Overview
  • About Us
    • Overview
    • Leadership
    • Board of Directors
    • Investors
    • Corporate Presentation
    • Mission and Values
  • Newsroom
    • Latest News
    • Media Inquiries
  • Careers
    • Join the team
  • Contact
    • General Inquiries
Slide

Newsroom

  • Latest News
  • Media Inquiries

Mace Rothenberg, M.D., Joins Aulos Bioscience Board of Directors

BOSTON and TEL AVIV, March 30, 2021 /PRNewswire/ — Aulos Bioscience, a biotechnology company developing highly differentiated interleukin-2 (IL-2)-binding monoclonal antibodies as therapeutics against solid tumors, announced today the appointment of Mace Rothenberg, M.D., to the company’s board of directors. With more than three decades of experience in medical oncology, academic research, and biopharmaceutical industry leadership, Dr. Rothenberg will contribute substantial strategic expertise in oncology drug development as Aulos designs and conducts clinical trials of its lead pipeline candidate, AU-007, in the coming months.

“We are delighted to welcome Mace to the Aulos board. He will bring deep insight and experience to our clinical development programs, along with the thoughtfulness, wisdom, and focus on patients that have been the hallmarks of his amazing career,” said Michael Ehlers, M.D., Ph.D., co-founder and executive chair of Aulos and venture partner and chief scientific officer at ATP, the life sciences venture capital firm that created Aulos in partnership with Biolojic Design, the Tel Aviv-based computational antibody design company that designed the Aulos lead asset.

Dr. Rothenberg most recently served as chief medical officer of Pfizer. In that role, he led the creation of the company’s combined Worldwide Medical & Safety organization, a trusted source of medical information and disease characterization and an innovator in quantitative, patient-centered, benefit-risk assessments. Prior to his appointment as CMO, Dr. Rothenberg led Pfizer’s oncology clinical drug development efforts. Over a 10-year period, his organization developed and obtained regulatory approvals for 11 new cancer medicines, including IBRANCE® (palbociclib), the first CDK 4/6 inhibitor for patients with HR+/HER2- advanced breast cancer, and XALKORI® (crizotinib), the first targeted medicine developed for patients with ALK+ non-small cell lung cancer. Before joining Pfizer, Dr. Rothenberg served on the faculties of Vanderbilt University Medical Center from 1998 to 2006 and the University of Texas Health Science Center-San Antonio from 1991 to 1998.

“We have long known about the antitumor potential of IL-2, but so far, activity sufficient for regulatory approval has only been observed in two diseases, melanoma and kidney cancer. By leveraging insights into the various ways in which IL-2 interacts with different kinds of immune cells, Aulos is developing a monoclonal antibody that has the potential to focus the effects of IL-2 on tumor-fighting T-cells and, in doing so, increase the depth of clinical responses and breadth of clinical activity that can be achieved with this cytokine. I am excited by the opportunity to collaborate with the talented team at Aulos and provide oversight and guidance as they work to bring AU-007 to patients,” said Dr. Rothenberg.

“The addition of Mace to our board is a testament to the promise of the unique approach to IL-2 engineered by the team at Biolojic and being developed by Aulos, and a great step forward as we build a world-class team here at Aulos,” said Aron Knickerbocker, president and CEO of Aulos Bioscience.

About Aulos Bioscience
Aulos Bioscience, an ATP company, is dedicated to revolutionizing patient care in cancer with highly differentiated immuno-oncology therapeutics. Aulos is initially developing unique IL-2 targeting antibodies that it believes have the potential to become best-in-class treatments for solid tumors. For more information, visit www.aulosbio.com.

Contact: info@aulosbio.com
Media inquiries: sjacob@appletreepartners.com

Aulos Bio favicon-32x32

AULOS BIOSCIENCE
700 LARKSPUR LANDING CIRCLE
SUITE 108
LARKSPUR, CA 94939

LinkedIn
twitter
  • Our Approach
  • Overview
  • Platform
  • Abstracts and Publications
  • Our Pipeline
  • Overview
  • About Us
  • Overview
  • Leadership
  • Board of Directors
  • Investors
  • Corporate Presentation
  • Mission and Values
  • Newsroom
  • Latest News
  • Media Inquiries
  • Careers
  • Join the team
  • Contact
  • General Inquiries
  • Terms of Use
  • Privacy
  • Social Media
  • CA Compliance
© Copyright 2023. All Rights Reserved.
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept All”, you consent to the use of ALL the cookies. However, you may visit "Cookie Settings" to provide a controlled consent.
Cookie SettingsAccept All
Manage consent

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.
CookieDurationDescription
cookielawinfo-checkbox-analytics11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional11 monthsThe cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy11 monthsThe cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
Functional
Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedbacks, and other third-party features.
Performance
Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.
Analytics
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.
Advertisement
Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.
Others
Other uncategorized cookies are those that are being analyzed and have not been classified into a category as yet.
SAVE & ACCEPT